FDA Approves Label Update for Kite’s Yescarta for Relapsed/Refractory Primary Central Nervous System Lymphoma

Feb 12, 2026 - 21:00
 0  1
SANTA MONICA, Calif.--(BUSINESS WIRE) February 6, 2026 -- Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) approved an update to the Yescarta (axicabtagene ciloleucel) prescribing information...

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0